Evista (raloxifene) is not a bisphosphonate. It belongs to a completely different drug class called selective estrogen receptor modulators, or SERMs. Both drug types are used to treat osteoporosis in postmenopausal women, which is why they’re often confused, but they work through different mechanisms and come with different benefits, risks, and daily routines.
How Evista Actually Works
Bisphosphonates slow bone loss by attaching directly to bone tissue and interfering with the cells that break bone down. Evista takes a different route entirely. As a SERM, it mimics the effects of estrogen in some parts of the body while blocking estrogen in others. In bone tissue, raloxifene acts like estrogen, boosting estrogen’s protective effect and slowing the bone thinning that accelerates after menopause. In breast tissue, it does the opposite, blocking estrogen from fueling cell growth.
This dual action is why Evista has two FDA-approved uses: treating osteoporosis and reducing the risk of invasive breast cancer in postmenopausal women. The FDA approved the breast cancer indication in 2007 based on results from the STAR trial, a large head-to-head study comparing raloxifene with tamoxifen. Bisphosphonates have no role in cancer prevention.
How Well It Prevents Fractures
Evista is strongest at preventing fractures in the spine. A meta-analysis found that raloxifene reduced vertebral fractures by 42% compared to placebo and reduced all clinical fractures by 18%. For women at the older end of the spectrum (around age 75), vertebral fracture risk dropped by about 31% regardless of their baseline fracture probability.
This is where bisphosphonates have a clear edge. Drugs like alendronate and risedronate have demonstrated reductions in both vertebral and hip fractures, while raloxifene’s evidence for hip fracture prevention is weaker. That distinction matters: hip fractures carry the highest risk of disability and death among osteoporotic fractures. For this reason, the Endocrine Society recommends raloxifene primarily for postmenopausal women at high fracture risk who have a low risk of blood clots and for whom bisphosphonates or denosumab aren’t appropriate, or who also have a high risk of breast cancer.
A Much Easier Daily Routine
One of the most practical differences between Evista and oral bisphosphonates is how you take them. Oral bisphosphonates come with strict instructions: take them first thing in the morning on an empty stomach, with a full glass of plain water, then stay upright and avoid eating or drinking anything else for 30 to 60 minutes. These rules exist because bisphosphonates can irritate the esophagus and are poorly absorbed alongside food or other drinks.
Evista has none of those requirements. The standard dose is one 60 mg tablet daily, taken at any time of day, with or without food. There are no posture restrictions. For people who struggled with the rigid bisphosphonate routine or experienced throat and stomach irritation from those drugs, this simplicity can be a meaningful advantage.
Different Side Effects and Risks
Because the two drug classes work through entirely different pathways, their risk profiles look nothing alike. Bisphosphonates are associated with gastrointestinal irritation (particularly in the esophagus), and rare but serious concerns include jawbone damage and unusual thigh fractures with long-term use.
Evista’s risks center on blood clots and cardiovascular effects. Raloxifene increases the risk of deep vein thrombosis and pulmonary embolism, with the highest risk during the first four months of treatment. If you’re facing surgery or any situation that keeps you immobilized for an extended period, raloxifene should be stopped at least 72 hours beforehand. The drug is contraindicated in anyone with a current or past history of blood clots, including deep vein thrombosis, pulmonary embolism, or retinal vein thrombosis.
There is also an increased risk of fatal stroke in postmenopausal women who already have coronary heart disease or significant risk factors for it. Raloxifene should not be used to prevent cardiovascular disease. The most common day-to-day side effects are hot flashes and leg cramps, which are quite different from the digestive complaints associated with bisphosphonates.
Who Is a Better Fit for Each
For most postmenopausal women with osteoporosis, bisphosphonates remain the first-line treatment because of their broader fracture protection, including at the hip. Evista fills a specific niche. Current guidelines from the Endocrine Society position it as a recommended option for women who meet a particular profile: those at high risk of vertebral fractures but low risk of blood clots, and for whom bisphosphonates or denosumab aren’t suitable. Women at elevated risk of breast cancer get an added benefit that no bisphosphonate can offer.
Evista is not recommended for premenopausal women, during pregnancy or breastfeeding, or alongside systemic estrogen therapy. It should also be used cautiously in women with liver problems or moderate to severe kidney impairment.
If you’re currently on a bisphosphonate and wondering whether Evista might work better for you, the decision usually comes down to your fracture risk profile, your history with blood clots, your breast cancer risk, and whether you’ve had trouble tolerating bisphosphonates. The two drugs aren’t interchangeable, but they serve overlapping goals through very different biology.